Accessibility Menu
Agenus Stock Quote

Agenus (NASDAQ: AGEN)

$4.05
(-5.6%)
-0.24
Price as of October 22, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$4.05
Daily Change
(-5.6%) $0.24
Day's Range
$4 - $4.26
Previous Close
$4.05
Open
$4.25
Beta
1.78
Volume
563,435
Average Volume
509,028
Market Cap
129M
Market Cap / Employee
$4.05M
52wk Range
$1.38 - $7.34
Revenue
-
Gross Margin
0.87%
Dividend Yield
N/A
EPS
-$7.15
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Agenus Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
AGEN-9.8%-94.76%-44.56%-100%
S&P+14.5%+93.32%+14.09%+370%

Agenus Company Info

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

News & Analysis

The Fool has written over 100 articles on Agenus.

Financial Health

General

Q2 2025YOY Change
Revenue$25.69M9.3%
Gross Profit$22.28M11.2%
Gross Margin86.72%1.5%
Market Cap$125.29M-64.4%
Market Cap / Employee$0.40M0.0%
Employees316-18.8%
Net Income-$30.01M45.2%
EBITDA-$13.61M49.3%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$9.53M-89.8%
Accounts Receivable$0.71M-1.4%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$285.07M18.8%
Short Term Debt$117.69M-31.4%

Ratios

Q2 2025YOY Change
Return On Assets-69.29%-3.2%
Return On Invested Capital67.41%-1050.5%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$20.22M47.7%
Operating Free Cash Flow-$20.22M47.0%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book-0.41-0.20-0.11-0.36-79.66%
Price to Sales0.740.600.371.26-42.83%
Price to Tangible Book Value-0.37-0.19-0.10-0.33-78.46%
Enterprise Value to EBITDA-17.14-19.11-44.99-39.6754.01%
Total Debt$420.60M$431.35M$416.94M$402.76M-2.15%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.